{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:34:24Z","timestamp":1791362064038,"version":"4.3.1"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100001151","name":"Australian Primary Health Care Research Institute, Australian National University","doi-asserted-by":"publisher","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}],"id":[{"id":"10.13039\/501100001151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001151","name":"Australian Primary Health Care Research Institute, Australian National University","doi-asserted-by":"publisher","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}],"id":[{"id":"10.13039\/501100001151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01372"],"award-info":[{"award-number":["PI17\/01372"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure. We aimed to characterize the population pharmacokinetics of piperacillin in plasma and provide optimized dosing recommendations for this patient population. A population pharmacokinetic analysis was conducted in patients who received piperacillin-tazobactam as part of the BEATLE study, which compared the efficacy, safety, and pharmacokinetic\/pharmacodynamic target attainment of \u03b2-lactams administered in extended infusion versus short 30 min infusion in adult hematological patients with febrile neutropenia. Monte Carlo simulations were performed to evaluate, for each dosing regimen, the probability of attaining (i) an efficacy target of unbound piperacillin concentrations above the minimum inhibitory concentration (MIC) of the bacteria for the entire dosing interval (100% \u0192\n                      <jats:italic toggle=\"yes\">T<\/jats:italic>\n                      <jats:sub>&gt;MIC<\/jats:sub>\n                      ), and (ii) a toxicity threshold of \u2265160 mg\/L. A total of 44 patients and 221 plasma concentrations were included. A one-compartment model best described piperacillin plasma pharmacokinetics, with Cockcroft-Gault creatinine clearance (CrCL) significantly influencing drug clearance. Dosing simulations showed that extended and continuous infusions were superior to short 30 min infusions in the attainment of 100% \u0192\n                      <jats:italic toggle=\"yes\">T<\/jats:italic>\n                      <jats:sub>&gt;MIC<\/jats:sub>\n                      , even for bacteria with low to intermediate MIC (\u22642\u20134 mg\/L). In patients with higher CrCL (&gt;90 mL\/min) or infections caused by less susceptible Gram-negative bacilli (MIC: 8\u201316 mg\/L), only continuous infusions of 12\u201316 g\/day were likely to achieve 100% \u0192\n                      <jats:italic toggle=\"yes\">T<\/jats:italic>\n                      <jats:sub>&gt;MIC<\/jats:sub>\n                      . These findings support the use of extended or continuous infusions of piperacillin in the initial management of patients with febrile neutropenia, particularly in patients with higher CrCL or when infections caused by less susceptible pathogens, such as\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      , are suspected.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01253-25","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:06:21Z","timestamp":1764068781000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-7231","authenticated-orcid":true,"given":"Julia","family":"Laporte-Amargos","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Bellvitge University Hospital","place":["L'Hospitalet de Llobregat, Spain"]},{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, University of Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-8430","authenticated-orcid":false,"given":"Marta","family":"Ulldemolins","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Bellvitge University Hospital","place":["L'Hospitalet de Llobregat, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"publisher"}],"name":"UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences (HMBS), The University of Queensland","place":["Brisbane, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-0292","authenticated-orcid":true,"given":"Mar\u00eda Patricia","family":"Hern\u00e1ndez-Mitre","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"publisher"}],"name":"UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences (HMBS), The University of Queensland","place":["Brisbane, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"publisher"}],"name":"UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences (HMBS), The University of Queensland","place":["Brisbane, Australia"]},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health","place":["Brisbane, Australia"]},{"id":[{"id":"https:\/\/ror.org\/05p52kj31","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, Royal Brisbane and Women's Hospital","place":["Brisbane, Australia"]},{"name":"Department of Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital","place":["Brisbane, Australia"]},{"name":"Division of Anesthesia Critical Care and Emergency and Pain Medicine, Nimes University Hospital, UR UM 103, University of Montpellier","place":["Nimes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rigo-Bonnin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL)","place":["L'Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Carmona-Torre","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03phm3r45","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Cl\u00ednica Universidad de Navarra, Navarra Institute for Health Research (IdiSNA)","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Huguet","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Institut Catal\u00e0 d\u2019Oncologia-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute","place":["Badalona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Puerta-Alcalde","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02a2kzf50","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Diseases Department, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Hospital Cl\u00ednic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, University of Barcelona","place":["Barcelona, Spain"]},{"id":[{"id":"https:\/\/ror.org\/0008xqs48","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Haematology, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, IDIBELL","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"del Pozo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03phm3r45","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Cl\u00ednica Universidad de Navarra, Navarra Institute for Health Research (IdiSNA)","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Torrent","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Institut Catal\u00e0 d\u2019Oncologia-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute","place":["Badalona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0683","authenticated-orcid":true,"given":"Carolina","family":"Garc\u00eda-Vidal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0008xqs48","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Haematology, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, IDIBELL","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Bergas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Bellvitge University Hospital","place":["L'Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Sastre-Escol\u00e0","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Bellvitge University Hospital","place":["L'Hospitalet de Llobregat, Spain"]},{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, University of Barcelona","place":["Barcelona, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Bellvitge University Hospital","place":["L'Hospitalet de Llobregat, Spain"]},{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, University of Barcelona","place":["Barcelona, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"id":[{"id":"https:\/\/ror.org\/0008xqs48","id-type":"ROR","asserted-by":"publisher"}],"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Gudiol","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00epner96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Bellvitge University Hospital","place":["L'Hospitalet de Llobregat, Spain"]},{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, University of Barcelona","place":["Barcelona, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"id":[{"id":"https:\/\/ror.org\/0008xqs48","id-type":"ROR","asserted-by":"publisher"}],"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"id":[{"id":"https:\/\/ror.org\/01j1eb875","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Catal\u00e0 d\u2019Oncologia","place":["L'Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091025"},{"key":"e_1_3_6_3_2","unstructured":"Averbuch D Guisado MA Akova M Baccelli F Blijlevens N Cordonnier C Vidal CG Mikulska M Mu\u00f1oz P Neofytos D Vanbiervliet Y Calandra T. 2024. Bacterial: febrile neutropenia \u2013 duration of therapy - new drugs. European Conference on Infections in Leukemia (ECIL). ECIL\u201110 bacterial group final recommendations. Available from: https:\/\/www.ecil\u2010leukaemia.com\/images\/ecil-10\/ECIL_10_-_bacterial_group_final_recommendations.pdf"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu027"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00294-06"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.12.009"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32835915c2"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00791-z"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.02.014"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.10.006"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04323-0"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.03.009"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9238-5"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003465-198603000-00013"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709751"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3038"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-005-0016-4"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.506187"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00654-17"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx209"},{"key":"e_1_3_6_26_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2025. Breakpoint tables for interpretation of MICs and zone diameters version 15.0. https:\/\/www.eucast.org."},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz248"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02340-14"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-59"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00311-17"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0750-y"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix646"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx427"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz319"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv123"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy258"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2842"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9779"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9803"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02747-15"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae058"}],"updated-by":[{"DOI":"10.1128\/aac.00740-26","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01253-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01253-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:01:00Z","timestamp":1767794460000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01253-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"alternative-id":["10.1128\/aac.01253-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01253-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01253-25"}}